The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - academic.oup.com
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory …
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …
Background Little is known about the real-world effectiveness of oral antivirals against the SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
H Pan, R Peto, AMH Restrepo, MP Preziosi… - The Lancet, 2022 - Elsevier
Summary Background The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …
Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high- risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …